References
- Baran R, Dawber P RP. Diseases of the nail and their management (2nd edn). Blackwell Scientific, Oxford 1994
- Goodfield M JD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126(Suppl 39)33–5
- Savin R C, Atton A V. Terbinafine in onychomycosis - a mini study. Int J Dermatol 1993; 32: 918–19
- Schroeff van der J G, Cirkel P KS, Crijns M B, et al. A randomised treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126(Suppl 39)36–9
- Denouel J, Keller H P, Schaub P, et al. Determination of terbinafine and its desmethyl metabolite in human plasma by high performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 663: 353–9
- Faergemann J, Zehender H, Denouel J, et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Vernereol 1993; 73: 305–9
- Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121–6
- Ryder N S. The mechanism of action of terbinafine. Clin Exp Dermatol 1989; 14: 98–100
- Ryder N S. Biochemical mode of action of terbinafine. Cutaneous antifungal agents: selected compounds in clinical practice and development, J W Rippon, R A Fromthing. Marcel Dekker Inc, New York 1993; 127–36
- Ryder N S. Terbinafine: a mode of action and properties of the squalene expoxidase inhibition. Br J Dermatol 1992; 126(Suppl 39)2–7
- Baudraz-Rosselet F, Rakosi T, Wili P B, et al. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126(Suppl 39)40–6
- Chan H L, Yang L I. An open study to compare the efficacy and tolerability of terbinafine with griseofulvin in onychomycosis. Terbinafine in the treatment of superficial fungal infections, S Shuster, M H Jafar. Royal Soc Med Sciences, London 1993; 45–7, [Proceedings]
- Cribier B, Grosshans E. Efficacité et tolérance de la terbinafine (Lamisil*) dans une série de 50 onychomycoses à dermatophytes. Ann Dermatol Venereol 1994; 121: 15–20
- Roberts D T. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994; 31(3S/Pt.2)S78–S81
- Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750
- Finlay A Y. Pharmacokinetics of terbinafine in skin and nail. Antifungal advance. Proceedings from a clinical evening. Asia Ltd, Hong Kong 1991; 16–19
- Zehender H, Cabiac M D, Denouel J, et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration and comparison with 3 main metabolites. Drug Invest 1994; 8: 203–10
- Finlay A Y, Lever L, Thomas R, et al. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1(Suppl 2)51–3
- Hofmann H, Brautigam M, Weidinger G, , the Lagos II Study Group, et al. Treatment of toenail onychomycosis. A randomized double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919–22